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1.0 Introduction 
Glyosaminoglycans (GAGs) are long unbranched polysaccharide chains composed of 
repeating disaccharide subunits of alternating uronic acid and glycosamine (GlcN) residues. 
These molecules have a large net negative charge as a result of a complex arrangement of 
N- and/or O-linked sulfate binding on the sugar moieties. Heparin is the best known GAG 
and is expressed exclusively by mast cells [1], Other GAGs include heparan sulfate (HS), 
chondroitin sulfate (CS), dermatan sulfate (DS) and keratan sulfate (KS). These are 
ubiquitously expressed on the extracellular matrix and bound, via serine residues, to protein 
cores on many cell surfaces in the form of proteoglycans (PGs) [2].  
Whilst heparin is well known for its anticoagulant properties, there is increasing evidence that 
heparin and other GAGs can influence cell functions through a diverse range of activities that 
include the regulation of cell survival, growth, differentiation and angiogenesis and invasion 
[3, 4, 5]. Although the molecular mechanism of the action of GAGs is not well understood, 
accumulating evidence suggests that the effects of heparan sulfate glycosaminoglycans may 
be attributable at least in part to their binding of the growth factors and regulating of their 
signaling [6, 7].  
GAGs show considerable variation in chain length and degree of sulfation on either sugar in 
the disaccharide subunit. In the case of HS, the disaccharide units are differentially sulfated 
on the C-6 carbon or N position of the GlcN, on C-2, or occasionally on C-3, of the GlcA/IdoA 
subunit [8]. The polysaccharide chain length coupled with the variation in the extent of 
sulfation, give rise to hundreds of potential polysaccharide structural combinations.  
GAGs have been implicated in a wide variety of pathology including respiratory failure [9], 
placental malaria [10] and cancer [11]. HS and CS have been shown to be important for the 
initial attachment of Merkel cell polyomavirus (MCV) to cells while 6-O-sulfated and N-
sulfated HS is important for the reporter vector entry [12] Determining the composition of 
these GAGs is important in understanding their role. Depolymerization of GAGs and analysis 
of their disaccharides is an important step in the characterization of GAGs. Depolymerization 
can be achieved using specific lyases which cleave the glycosidic linkage between a 
hexosamine and a hexuronic acid thus introducing an unsaturated bond (absorbing at 232 
nm) between the C4 and C5 of the hexuronic acid. GAGs can also be depolymerized 
chemically by mild hydrazinolysis and subsequent deaminative cleavage with nitrous acid 
[13]. This method retains the original epimeric nature of the hexuronic acid but loses 
information about the N-sulfation or N-acetylation because the resulting disaccharide 
comprise a hexuronic acid linked to a 2,5-anhydrohexose bearing an aldehyde group [13]. 
Enzymatic depolymerization of heparin/heparan sulfate (hep/HS) with heparinises give rise 
to twelve disaccharides out of which only eight are commonly seen in normal organisms [14, 
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15]. The other four (N-unsubstituted glucosamine) are rare and are believed to result from 
the loss of labile N-sulfate groups during isolation or incomplete modification (N-
deactylase/N-sulfotransferase) during hep/HS biosynthesis [14]. These twelve hep/HS 
disaccharides are commercially available. 
Previous techniques used for the compositional analysis of GAG disaccharides include liquid 
chromatography (LC) with UV [16], fluorescence [17], and MS detection. These GAG 
disaccharides are hydrophilic and hence will not be well retained on a reverse phase (RP) 
column. Underivatized GAG disaccharides can be analyzed directly using a variety of 
separation methods including hydrophilic interaction liquid chromatography (HILIC)-MS. 
However, co-elution of disaccharides has been reported [13].  To overcome these issues, 
GAG disaccharides may be derivatized with a hydrophobic fluorophore which increases their 
retention on RPLC and may improve MS sensitivity. Derivatizing reagents employed for this 
include 4,4-difluoro-5,7-dimethyl-4-bora-3a-diaza-s-indacene-3-propionic acid (BODIPY) and 
2-aminobenzamide [14]. Retention of GAG disaccharides and oligosaccharides may also be 
improved using ion pair RPLC with reagents such as tetrabutylammonium [18], n-hexylamine, 
and n-pentylamine. [19] However, each of these has specific additional drawbacks that make 
analysis of GAG disaccharides problematic, particularly when analyzing biological samples. 
These require long run times and some of the non-volatile ion pairing reagents contaminate 
the MS interface [20]. Capillary electrophoresis with laser-induced fluorescent detection [21] 
and fluorophore-assisted carbohydrate electrophoresis (FACE) [22] have also been 
employed in GAG disaccharide analysis. However, both of these methods could suffer from 
poor reproducibility of migration times. 
There is therefore a need to develop a more rapid, selective and sensitive method to quantify 
levels of GAG disaccharides in biological samples. In this article, we report a method of rapid 
separation and detection of twelve heparin/heparan sulfate disaccharides and an internal 
standard in 11 min. This method demonstrates excellent reproducibility, which does not 
require the specialized separation techniques needed for the separation of native 
disaccharides and has been successfully applied to the comparison of disaccharide 
expression in a variety of human cancer cell lines. Derivization-based methods frequently 
report the use of highly toxic reducing agents such cyanoborohydride. The method described 
uses the less toxic 2-methylpyridine borane. This analysis employs an optimized selected ion 
recording (SIR) precolumn RP-UPLC-MS method based on 2-aminoacridone derivatization 
without the need to remove excess unreacted reagent. We have applied this method to the 
analysis of disaccharide levels in a variety of human cell lines.  
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2.0 Materials and methods  
2.1 Materials 
Actinase (from Streptomyces griseus), 2-aminoacridone (AMAC), 2-methylpyridine borane 
complex,  heparan sulfate (sodium salt from bovine kidney), anion exchange spin columns, 3 
kDa, and 10 kDa molecular weight cut off filters were purchased from Sigma-Aldrich, (Poole, 
UK). Twelve unsaturated heparin/HS disaccharides (∆UA,2S - GlcNS,6S; ∆UA,2S-GlcNS; 
∆UA,2S - GlcNAc,6S; ∆UA-GlcNS,6S; ∆UA-GlcNS; ∆UA-GlcNAc; ∆UA,2S- GlcNAc; ∆UA-
GlcNAc,6S; ∆UA,2S - GlcN; ∆UA,2S-GlcN, 6S; ∆UA-GlcN, 6S; ∆UA–GlcN) and an internal 
standard (∆UA,2S - GlcNCOEt,6S) were purchased from Iduron (Manchester, UK).  
Heparinases (from Flavobacterium heparinum) I, II, and III were also purchased from Iduron 
(Manchester, UK). Acetic acid, LC-MS grade dimethyl sulfoxide (DMSO), LC grade 
ammonium acetate, methanol, and UPLC water were purchased from Fisher Scientific, 
(Loughborough, UK).  
 
2.2 Cell culture 
GAGs were extracted from a variety of human cell lines grown in our laboratory. These 
included cell lines from ovarian adenocarcinoma (OVCAR-3), metastatic breast 
adenocarcinoma (MDA-468), acute myeloid leukaemia (MOLM-13), choriocarcinoma (BeWo) 
and a  colon cancer cell line (HCT116). Cells were incubated at 37 °C in media containing 
10 % fetal bovine serum , 1 % penicillin and streptomycin (Thermofisher, Hemel Hempsted, 
UK) in an atmosphere containing 5 % CO2. All cells were cultured using RPMI 1640 medium 
except HCT116 cells which were cultured using DMEM (Sigma) and BeWo cells were 
cultured using DMEM:F12. All cell lines were purchased from LGC standards (Teddington, 
UK) with the exception of MOLM-13 cells (DSMZ, Braunschweig, Germany) and were 
cultured for at least two passages prior to GAG analysis.  
 
2.3 Extraction and enzymatic depolymerization of heparin/HS disaccharides from 
cells 
We used an adaptation of the extraction method reported by Han, et al. [23] and Volpi, et al. 
[24] for the extraction of heparin/HS from cells. Briefly, cells grown to confluence were 
scraped gently from the flask and washed in 100 mM phosphate buffered saline. They were 
then incubated with actinase (20 mg/mL) for 18 h to proteolyse intracellular and membrane 
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bound proteins. The resulting solution was filtered to remove particulates, and the peptides 
removed using a 10 kDa molecular weight cut-off filter. The retenate was lyophilized and re-
suspended in 8 M urea with 2 % CHAPS. Anion exchange spin columns were used to extract 
GAGs from this mixture, washed with 200 mM NaCl and subsequently eluted with 16 % NaCl. 
This solution was desalted using a 3 kDa molecular weight cut-off filter, lyophilized, and re-
suspended in 50 mM phosphate buffer (pH 7.0). Time-controlled enzymatic depolymerization 
of the GAGs was achieved by the addition of 3 mIU of heparinase I, II, and III at 37 oC for 48 
h as described above. The solution was then heated in boiling water for 10 min and 
centrifuged at 12,000 x g for 10 min to remove denatured proteins. The supernatant was 
collected and 0.5 µL of internal standard (∆UA,2S - GlcNCOEt,6S, 1 mg/mL) was added. 
This was then lyophilized, derivatized with AMAC and analyzed using UPLC-MS. 
In order to determine the recovery of disasccharides from this extraction procedure, heparan 
sulfate standards (5 and 10 µg) were extracted and disaccharides quantified as descibed 
above (extracted HS). In addition, the same amount of HS was directly digested with 
heparinases without prior extraction and then further processed as above (unextracted HS). 
For each HS subunit the recovery was determined as the amount detected from extracted 
HS as a percentage from that obtained from unextracted HS. 
 
2.4 Derivatization of heparin/HS disaccharide standards 
The heparin/HS disaccharides were derivatized pre-column using AMAC employing a 
modification of the method reported by Volpi, et al. [24]. Briefly, solutions containing 
heparin/HS disaccharides were lyophilized and re-dissolved in  a solution of 0.1 M AMAC in 
a mixture of DMSO and acetic acid (17 : 3, v/v). The mixture was then incubated at room 
temperature for 15 min and then an equal volume of 2-methylpyridine borane complex (1 M) 
in acetonitrile was added. This mixture was centrifuged at 10,000 x g for 1 min at room 
temperature and incubated at 45 oC for 4 h. Prior to injection the sample volume was 
adjusted to 200 µL with a mixture of DMSO : water (1 : 1, v/v).  
 
2.5 Optimization of AMAC derivatization of heparin/HS disaccharides 
To determine the optimal concentration of AMAC, 12 heparin/HS disaccharides and the 
internal standard (0.5 µg each) were incubated with different concentrations of AMAC over a 
range of 0.53 – 4.20 mg/mL using the procedure described in Section 2.4. In order to 
determine the optimum temperature for derivatization, the optimal AMAC concentration (2.1 
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mg/mL) was used to derivatize a mixture of 12 heparin/HS disaccharides containing 0.5 µg 
of each disaccharide as described above. The samples were then incubated at 37, 45, or 65 
oC for 4 h and subsequently analyzed. To optimize incubation time a mixture of 12 
heparin/HS disaccharides was derivatized under optimal conditions of AMAC concentration 
and incubation temperature for 2, 4, 6, and 8 h and subsequently analyzed as described 
above.  
 
2.6 Optimization of UPLC-MS conditions  
Individual heparin/HS disaccharides were derivatized using optimized conditions described 
in Section 2.5 and analyzed using UPLC-MS as described above. A mixture of 12 AMAC-
derivatized heparin/HS disaccharides was injected at a concentration of 1 µg/mL for the 
optimization of desolvation temperature, cone and extractor voltages. MS detection was 
based on the most intense ions observed from trisulfated and disulfated disaccharides while 
single ions were seen for the mono and non-sulfated disaccharides. Desolvation temperature, 
cone voltage and extractor voltage were varied between 300 – 400 oC, -15 – 75 V and -1 – 4 
V respectively. For all further experiments, the optimized conditions for AMAC concentration, 
incubation conditions, desolvation temperature, and extractor voltage were 2.1 mg/mL, 4h, 
45 oC for 4 h, 350 °C and 3 V respectively. Individual cone voltages were used for each of 
the derivatized disaccharides. 
2.7 UPLC-MS conditions 
A Waters Acquity H-Class UPLC system with an SQ Detector 2 was used for the LC-MS 
analysis. Separation was performed using an ACQUITY BEH Shield RP 18 column (1.7 µm, 
2.1 x 150 mm; Waters, Ireland, UK) maintained at 45 °C. Separation was achieved using 
gradient elution. Solvent A and B were 80 mM ammonium acetate and methanol respectively 
and were delivered at a flow rate of 0.3 mL/min. The gradient was as follows; Solvent A and 
12 % B for 1.7 min followed by a linear gradient of 12 – 15 % B from 1.7 - 5 min, 15 -30 % B 
from 5 - 10 min, 30 – 100 % B from 10 – 10.7, 100 % B from 10.7 – 13.3 mins, 100 – 12 % B 
from 13.3 – 13.7 mins and 12 % B from 13.7 – 18 mins. An aliquot (5 µL) of each sample 
was injected onto the column. 
Eluates were detected using a single quadrupole mass spectrometer equipped with an ESI 
source operated in negative ion mode. The capillary voltage was set to -3 kV; source 
temperature, 150 oC; source gas flow, 800 L/hr and cone gas flow 50 L/hr. The MS probe 
position was optimized to 4 mm vertical and 5.1 mm horizontal for the detection of AMAC-
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derivatized heparin/HS disaccharides.  Data was acquired using selected ion recording (SIR) 
and was analyzed using the MassLynx ® software version 4.1. 
 
2.8 Linearity, Limits of detection, quantification and reproducibility 
 A mixture of 12 Heparin/HS disaccharides and an internal standard (∆UA,2S - 
GlcNCOEt,6S) were derivatized and analyzed in duplicate using optimum conditions at a 
range of concentrations (0.019-10 µg/mL) of each disaccharide. Simple least squares 
regression analysis was used to determine linearity. The limits of detection and quantification 
were the lowest concentration that produced a signal:noise ratio of at least 3:1 and 10:1 
respectively. Reproducibility was determined at concentrations of 0.625, 1.25, and 5 µg/mL 
and was defined as the coefficient of variation from five consecutive injections. 
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3.0 Results and discussion 
Prior to derivatization studies, we conducted extensive studies to determine the optimum 
conditions for efficient separation of disaccharide subunits using HPLC. We found that 
effective separation of all thirteen disaccharides could be achieved in 11 min. With additional 
column reconditioning prior to analysis of the next sample, this gives a total run time of 18 
min. 
  
3.1 Optimization of Derivatization conditions 
Figure 1a shows the effect of AMAC concentration on ion intensity (LC-peak area). We found 
that the optimum concentration was 2.1 mg/mL. This concentration achieved the highest LC-
peak area for all except two of the disaccharides (∆UA– GlcN and ∆UA,2S – GlcNS). This 
concentration was used for all subsequent experiments. Interestingly, lower LC-peak areas 
were observed at higher AMAC concentrations. This may be attributed to signal suppression 
due to excess unreacted AMAC. It was also observed that the same concentration of 
different disaccharides produced significantly different LC-peak areas. It seems likely that 
this is due to differences in their efficiencies of ionization with ∆UA,2S – GlcNAc and ∆UA,2S 
– GlcNS,6S producing the highest and lowest LC-peak areas respectively with a ten-fold 
difference between them. 
The optimum temperature for derivatization was found to be 45 °C. Above this temperature a 
reduction in signal intensity was observed with all disaccharides except for ∆UA - GlcN, ∆UA 
–GlcN,6S, ∆UA,2S–GlcN and ∆UA,2S–GlcN,6S (Fig 1b). Subsequent analysis revealed that 
this reduction in signal intensity of the N-substituted disaccharides at higher temperatures 
was due to the loss of sulfonic groups during derivatization resulting in the formation of N-
unsubstituted HS disaccharide forms.  Thus, ∆UA,2S-GlcNS, 6S →∆UA, 2S-GlcN, 6S, 
∆UA,2S-GlcNS →∆UA,2S-GlcN, ∆UA-GlcNS, 6S → ∆UA-GlcN, 6S, and ∆UA-GlcNS → ∆UA-
GlcN. Some loss of these sulfonic groups was observed at 45 oC. Previous studies have 
noted that GAG N-sulfate groups are labile and may be lost during dervatization [14]. This 
breakdown is demonstrated using ∆UA, 2S-GlcNS,6S as an example (Figure 1c). At 45oC, 
∆UA, 2S-GlcN,6S was formed during derivatization. When the temperature was increased to 
65oC, three N-unsubstituted (∆UA, 2S-GlcN, 6S, ∆UA-GlcN, 6S, and ∆UA, 2S-GlcN) and one 
N-substituted HS disaccharide (∆UA-GlcNS) were formed. We did not see any loss of sulfo 
groups from N-unsubstituted disaccharides during derivatization. 
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The reduction in the MS signal for the non-sulfated N-substituted disaccharide (∆UA–GlcNAc) 
may be due to the breakage of the glycosidic bond linking Glc and GlcNAc with increasing 
derivatization temperature. The resulting non-sulfated GlcNAc–AMAC residue would only be 
minimally ionized in the ESI negative ion mode employed in this work.  
For all subsequent experiments, an incubation temperature of 45 0C was used for 
derivatization in order to optimize the signal intensity and minimize the loss of sulfonic 
groups. Figure 1d shows single ion recording chromatograms of ∆UA – GlcNS at three 
different incubation temperatures. It was noted that the LC-peak for this disaccharide split 
with no baseline separation. A likely explanation for this phenomenon is anomeric 
interconversion. Similar findings have been reported previously [13]. These authors found 
that interconversion between the α and β forms occurred with one form predominating at 
increased temperature. In the present study significant interconversion was detected at 
65 °C but only minimal interconversion occured at 45 °C. 
The effect of AMAC incubation time is shown in Figure 1e. As expected, the lowest LC-peak 
areas for all the disaccharides were observed at 2 h. The LC-peak areas of the N-substituted 
disaccharides peaked at 4 h with most of them decreasing thereafter. The exceptions to this 
trend were the N-unsubstituted disaccharides with their LC-peak areas increasing with 
increased incubation time. The reason for this observation can be attributed to the loss of the 
labile N-sulfo group of the N-substituted GAG disaccharides with prolonged exposure to heat 
during derivatization. This resulted in the formation of the N-unsubstituted disaccharides 
during derivatization with a resultant increase in their amounts. The N-unsubstituted 
disaccharides produced in this way cannot be distinguished from the ones originally present 
in the sample during separation and MS detection since they have the same mass and 
retention times. 
In summary, the optimum AMAC derivatization conditions for this method is 0.210 µg of 
AMAC with 4 h incubation at 45 0C. 
 
3.2 Optimization of MS conditions 
Initial MS conditions were as follows; desolvation temperature, cone voltage and extractor 
voltage were between 350oC, -50 V and -2.5 V respectively. Using these conditions, we were 
able to detect all thirteen derivatized HS disaccharides tested. The molecular weight and 
disaccharide ions detected using selected ion recording (SIR) of AMAC-derivatized 
heparin/HS disaccharides are shown in Table 1. For several of these, multiple ions were 
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detected which represent loss of sulfonic groups which are likely to result from in-source 
fragmentation. It is notable that with a single exception the same disaccharide subunits that 
showed loss of sulfonic groups during high temperature derivatization above also show 
multiple ions during ionization. Figure 2b also shows MS spectra for two of these (∆UA,2S–
GlcNS,6S and ∆UA,2S–GlcNAc,6S) confirming this. For others, only single ions were 
detected by MS. It was observed during optimization of derivatization conditions that certain 
disaccharides are more labile than others. Notably, doubly charged species were seen for 
disaccharides with more than one sulfate group. This can be explained by the loss of protons 
from disaccharides with two or more sulfonic acid groups and can be linked to the pH of the 
mobile phase. 
Figure 2a shows the effect of different cone voltages (-15 to -75 V) on the LC-peak area of 
derivatized HS disaccharide subunits. The optimum voltage was found to be in the the range 
-20 to -55 V depending on the subunit. Table 2 shows the optimal cone voltage for each 
subunit. These voltages were used in subsequent experiments. Lower cone voltages were 
optimum for lower m/z values and vice versa. Optimum cone voltage may be impacted by 
many factors. In-source fragmentation is certainly an important factor here. In-source 
fragmentation at higher cone voltages in ESI-MS operated in the negative mode has 
previously been reported [25].  
As a group, the disaccharides that were detected using their [M-2H]2- species had lower m/z 
values and required lower cone voltages for optimal signal intensities (LC-peak areas) with 
signal intensity decreasing with further increase in cone voltage. This can be explained by a 
reduction in in-source fragmentation thus preserving the parent ion, and promoting the 
formation of [M-2H]2- species at a lower cone voltage. Notably, in-source fragmentation is 
promoted at high cone voltages. This is clearly seen in Figure 2b using ∆UA,2S – 
GlcNS,6S and ∆UA,2S – GlcNAc,6S at a higher concentration (100 µg/mL) as examples. 
The signal intensity of the other disaccharides detected using their [M-H]- and [M-SO3-H]- 
species increased with increasing cone voltage, peaked, and decreased afterwards. The 
decrease most likely resulting from an increased in-source fragmentation of the monitored 
ion at higher cone voltages. Our results can be explained by both an increase in in-source 
fragmentation at higher cone voltages and differential ionization. 
Figure 2c and d show the effect of extractor voltage and desolvation teemperature on signal 
intensity. It is clear that the optima are 3V and 350°C respectively for all derivatized subunits. 
It can be seen that there is more efficient solvent evaporation with increasing temperature up 
to 350°C. However, further temperature increase leads to in-source fragmentation and 
consequent loss of signal. This can clearly be seen in the spectra of ∆UA,2S – 
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GlcNS,6S (Fig 2e). This was studied at a higher concentration and a cone voltage of -60 V 
where fragmentation is promoted in order to show this. With increasing temperature, the ion 
assigned to ∆UA,2S – GlcNS,6S with the loss of two sulfonic group ([M-2SO3-H]- , m/z 610) 
relative to that with the loss of one sulfonic group (([M-SO3-H]- , m/z 690) is increased.  
3.3 Chromatography of GAG subunits 
Based on these results further analysis was carried out using the optimum cone voltage for 
each derivatized HS disaccharide with an extractor voltage -3 V and desolvation temperature 
of 350 °C. From the MS analysis alone there were a number of disaccharides with m/z 
values close to 610 (∆UA,2S – GlcNS, ∆UA–GlcNS,6S, ∆UA–GlcNS, ∆UA,2S–GlcN and 
∆UA–GlcN, 6S). In addition, ∆UA,2S–GlcNAc and ∆UA–GlcNAc,6S both had similar m/z 
values (~652). However, using the UPLC conditions described each of these eluted at a 
different retention time and each can be easily quantified. Figure 3 shows the single ion 
recording (SIR) chromatograms of a mixture of AMAC-derivatized HS disaccharides run 
using the optimized conditions described above. It was notable that the separation and 
quantification of the thirteen HS disaccharides was achieved within approximately 11 min 
with good LC-peak shape. We are not aware of any previous reports of LC-MS-based 
methods of GAG disaccharide analysis with such rapid analysis time. The run time of the 
current method is significantly shorter than previous studies of AMAC-derivatized GAG 
disaccharides LC-MS analysis. These have reported run times of 50-60 min [14, 24]. 
The derivatized disaccharides eluted in order of increasing hydrophobicity with the tri-
sulfated disaccharide eluting first followed by di- and then mono-sulfated subunits and the 
non-sulfated subunits eluted last. The only exception to this was the mono-sulfated ∆UA – 
GlcNS which eluted within the retention window of the di-sulfated subunits. This order of 
elution has been reported previously [14]. It is interesting to note that within the elution 
window for di-sulfated disaccharides, those which are N-sulfated eluted before those which 
are n-acetylated. This same pattern was also observed for the mono-sulfated subunits. This 
order of elution can also be explained by differences in hydrophobicity between n-sulfated 
and n-acetylated subunits. Differences in hydrophobicity may also explain the observation 
that, in general, 6S sulfated subunits eluted prior to 2S subunits.   
The analysis of underivatized GAG disaccharides either by direct MS infusion or with 
specialized separation techniques including strong anion exchange [17], graphitized carbon 
LC [26] and HILIC columns [13] has been reported previously. The key advantage of these 
methods is that loss of disaccharides during derivatization is avoided but there are several 
disadvantages associated with direct analysis. Separation using graphitized carbon has 
been shown to affect the recovery of the trisulfated disaccharide because these species are 
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disproportionally retained and co-elution of disaccharides has been reported with HILIC [13]. 
In addition, a sample solvent of high organic concentration is required for HILIC 
chromatography, which may result in solubility issues as GAG disaccharides are polar. With 
ion exchange chromatography, the zwitterionic nature of N-unsubstituted disaccharides may 
result in poor retention [27]. Analysis of underivatized GAG disaccharides from commercially 
available GAG oligosaccharides and purified samples by tandem MS without LC separation 
has also been reported [28, 29, 30, 31]. These methods are complex and require a relatively 
expensive tandem MS to achieve the collision induced dissociation (CID) necessary to yield 
diagnostic ions for the differentiation of sulfational positional isomers. In addition, many of 
these direct analysis methods may be significantly affected by the numerous substances 
present in biological samples if GAGs are not purified before analysis. Size exclusion 
chromatographic methods have also been reported for the analysis of underivatized GAG 
disaccharides [27, 32]. However, these methods also require tandem MS in order to resolve 
sulfational positional isomers which co-elute [13] in addition to long run times of over 100 
minutes.  A previous study has analysed GAG disaccharides from heparin sulphate using 
direct SEC-LC/MS and MS/MS also revealed ∆UA–GlcNAc to be the most abundant 
disaccharide [32]. They found that 10 ug starting material was required in order to quantify 
disaccharides. However, the indirect LC/MS analysis with AMAC used in our study required 
only 5 ug starting material and required a significantly shorter rune time. Thus, our method 
overcomes these challenges and consequently a significantly shorter run time, good 
resolution and peak shape is achieved. In addition, there is no co-elution of disaccharides, 
the recovery of highly sulfated disaccharides is not problematic, and the relatively expensive 
tandem MS is not required. Derivatization with AMAC increases the hydrophobicity of these 
polar HS disaccharides. Increasing hydrophobicity increases ESI response as the 
hydrophobic ions have an increased affinity for the droplet surface thus entering the gas 
phase more readily [33, 34]. Hydrophobic analytes can also be well separated from 
potentially ion suppressing compounds and salts [34] thus reducing interference from any 
contaminating material that maybe be present in biological samples. Our method also 
permits UV/fluorescent detection due to AMAC derivatization thus can be adapted for use in 
laboratories without mass spectrometers. 
 
 
3.4 Method validation 
There was a clear linear relationship between the subunit concentration and the LC-peak 
area for each subunit across the range of concentrations tested (0.02-10 µg/mL). The limits 
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of detection and quantification varied between different subunits (Table 3) and ranged from 
0.02 - 0.15 and 0.02 - 0.31 µg/mL respectively. The mono-sulfated ∆UA,2S – GlcNAc 
showed the greatest ionization capacity with an LOD of 0.02 µg/ml. The linearity (r2) of this 
method (0.9747 – 1) is similar to previously reported [14], however, our LODs were higher. 
The precision (CV) of this method, based on five repeat measures at three concentrations 
ranged from 0.64 – 9.02 % at 0.625 µg/mL, 0.54 – 3.20 % at 1.25 µg/mL, and 0.39 – 1.57% 
at 5 µg/mL. There was little variation between disaccharide subunits but the precision was 
lowest at lower concentrations. This precision is within the range (<15%) accepted by the US 
Food and Drug Administration (FDA) and European Medicines Agency (EMA) for 
bioanalytical methods [35, 36] 
Table 4 shows the recovery of heparan sulfate disaccharides following extraction of HS as 
described in the methods. Six subunits were quantifiable from HS after extraction.  As 
expected, the recovery is better with higher amounts of starting material (10 µg) compared to 
5 µg irrespective of disaccharide. The highest disaccharide recovery is seen for ∆UA – 
GlcNAc as expected because it is the most abundant disaccharide seen in the HS standard. 
This bias in recovery may influence the compositional analysis of the disaccharides 
recovered from different sources. The reason for this poor recovery may be linked to the 
numerous steps involved in the extraction, depolymerization, and derivatization of these 
GAG disaccharides. 
3.5 Heparin/HS disaccharide composition of HS standard and cell lines 
We found that the non-sulfated ∆UA–GlcNAc was the most abundant disaccharide present in 
HS standard comprising, about half of all disaccharide subunits (Fig 5, Table 4). ∆UA–
GlcNAc,6S comprised about 20 % of HS and the disaccharides ∆UA,2S–GlcNS and 
∆UA,2S–GlcNAc were the least abundant representing 0.5 and 0.7% respectively. 
Compositional analysis of porcine intestinal mucosal HS by fluorescent and UV detection of 
heparan sulfate was previously carried by Deakin & Lyon [17]. They also found that ∆UA–
GlcNAc was the most abundant disaccharide. Our other results were in broad agreement; 
the only exceptions being that we have found much higher levels of ∆UA–GlcNAc,6S and 
much lower concentrations of ∆UA–GlcNS,6S (21.8% and 12% respectively, Table 5). We 
were also able to detect an additional disaccharide not seen in the other study (∆UA,2S–
GlcNAc). An advantage of our method is the use of a combination of retention time and m/z 
that provides an unequivocal identification of each HS disaccharide. In addition, we believe 
that the additional use of an internal standard improved reproducibility between runs. Finally, 
we have used single ion monitoring for each disaccharide. This selective approach may also 
enhance sensitivity. Thus, this difference may be due to the increased sensitivity of our 
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method or the difference in the source of HS as we used HS from bovine kidney. The relative 
abundance of disaccharides present in heparan sulfate is also broadly in agreement with that 
reported by Gill et al. [13] with the non-sulfated ∆UA–GlcNAc and monosulfated ∆UA–
GlcNAc,6S as the most abundant disaccharides present. However, we found that the 
disulfated ∆UA,2S–GlcNS was significantly less common (0.5% of total) compared to 
previous reports (8.3% of total, [13]).  
In comparison to the HS the cell lines generally comprised significantly less of the non-
sulfated HS disaccharide ∆UA–GlcNAc and the trisulfated ∆UA,2S–GlcNS,6S. We are 
unaware of any previous reports quantifying expression of specific HS disaccharides in 
human cell lines. However, the composition of HS disaccharides in this study was broadly in 
agreement with a previous report that has examined expression from a canine kidney cell 
line (MDCK) [18] in that the most abundant cell line was ∆UA – GlcNAc. However, their 
study did not examine the absolute concentrations of HS disaccharides. There were 
significant differences in the heparan sulfate disaccharide composition between the various 
cell lines tested. For the majority of cell lines the non-sulfated ∆UA–GlcNAc was the most 
abundant disaccharide (Fig 4, Table 5) as is also the case for heparan sulfate itself. The only 
exception to this was in the breast cancer cell line MDA-468 where the monosulfated ∆UA–
GlcNAc,6S had a slightly higher concentration. 
Many studies have demonstrated regulatory effects of glycosaminoglycans on cell function 
including proliferation, differentiation and invasion [3, 37, 38]. In addition, several studies 
have examined the effects of specific HS and CS disaccharides on cell function. Poh et al. 
[39] found that CS disaccharides inhibit aggressive triple negative breast cancer cell viability. 
Previous studies have reported that addition of specific HS disaccharides, notably 
monosulfated ∆UA-GlcNS significantly increased the production of the hepatocyte growth 
factor (HGF) in vitro and in vivo [40, 41]. HGF is known to contribute to the tumorogenic 
phenotype in many cancers and it is interesting to note that relative expression of this 
disaccharide was elevated in many of the cancer cell lines tested here compared to HS.  In 
order to understand how specific disaccharide expression may be associated with tumour 
development it will be useful to apply the methodology described here to compare their 
expression in tissues from various cancer stages and with tissues from unaffected 
individuals. 
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4.0 Conclusion 
We have used this methodology to show the rapid separation and detection of AMAC 
derivatized heparan sulfate disaccharides with a total run time of only 18 min. The method 
employed SIR in contrast to the commonly used TIC methods. Extracted ion chromatograms 
have been shown to be about 10 times more sensitive than TIC. We have shown that there 
are differences in both the total amount and composition of disaccharides between different 
tissue types. Further studies are needed to examine the significance of these differences. 
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Table 1: Heparin/HS disaccccharide structural codes, MS ions, and assigniment. Extractor 
voltage: 3 V, and desolvation temperature: 350°C. MS ions in bold were the most intense 
seen and used for DS MS detection. 
HS DS structural code MS ion (DS + AMAC) Assignment 
∆UA,2S –GlcNS,6S 769.9 
690.2 
610.0 
384.5 
344.5 
304.7 
[M-H]- 
[M-SO3-H]- 
[M-2SO3-H]- 
[M-2H]2- 
[M-SO3-2H]2- 
[M-2SO3-2H]2- 
∆UA,2S – GlcNS 690.2 
610.0 
344.0 
304.5 
[M-H]- 
[M-SO3-H]- 
[M-2H]2- 
[M-SO3-2H]2- 
∆UA,2S – GlcNAc,6S 732.3 
652.4 
365.7 
[M-H]- 
[M-SO3-H]- 
[M-2H]2- 
∆UA – GlcNS,6S 690.1 
610.0 
344.0 
304.5 
[M-H]- 
[M-SO3-H]- 
[M-2H]2- 
[M-SO3-2H]2- 
∆UA – GlcNS 610.3 [M-H]- 
∆UA – GlcNAc 572.3 [M-H]- 
∆UA,2S – GlcNAc 652.3 [M-H]- 
∆UA – GlcNAc,6S 652.2 [M-H]- 
∆UA,2S – GlcNCOEt, 6S 372.6 [M-2H]2- 
∆UA,2S – GlcN 610.3 [M-H]- 
∆UA,2S – GlcN, 6S 344.6 [M-2H]2- 
∆UA – GlcN, 6S 610.2 [M-H]- 
∆UA – GlcN 530.2 [M-H]- 
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Table 2: Optimal cone voltage for the different heparin/HS DS  
HS DS subunit Optimal cone voltage (-V) 
∆UA,2S – GlcNS,6S  20 
∆UA,2S – GlcNS 55 
∆UA,2S – GlcNAc,6S 25 
∆UA – GlcNS,6S 55 
∆UA – GlcNS 55 
∆UA – GlcNAc 50 
∆UA,2S – GlcNAc 55 
∆UA – GlcNAc,6S 55 
∆UA,2S – GlcN 50 
∆UA,2S – GlcN,6S 20 
∆UA – GlcN,6S 55 
∆UA – GlcN 50 
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Table 3: Monitored MS ions, retention time, limits of detection, limits of quantitation, r2, slope, 
and intercept of the method. LOD and LOQ were determined using signal:noise 3:1 and 10:1 
respectively. 
HS DS structural 
code 
Monitored 
MS ion 
(m/z) 
Retention 
time 
(min) 
LOD 
(µg/ml) 
LOQ 
(µg/ml) 
r2 Slope Intercept 
∆UA,2S –GlcNS,6S 384.5 2.5 0.07 0.11 0.9999 1269.6 -83.46 
∆UA,2S – GlcNS 610.0 4.0 0.08 0.14 0.9998 1955.1 -124.63 
∆UA,2S – 
GlcNAc,6S 
365.7 6.1 0.09 0.18 0.9999 1720.2 -115.7 
∆UA – GlcNS,6S 610.0 3.2 0.08 0.17 0.9999 1947.9 -79.96 
∆UA – GlcNS 610.3 5.4 0.12 0.17 0.9993 2457.7 -243.67 
∆UA – GlcNAc 572.3 10.1 0.06 0.09 0.9998 3051.4 -150.75 
∆UA,2S – GlcNAc 652.3 8.7 <0.02 0.02 0.9999 12007 144.94 
∆UA – GlcNAc,6S 652.2 7.6 0.13 0.19 0.9997 2756.2 -357.42 
∆UA,2S – 
GlcNCOEt, 6S 
372.6 8.3 0.07 0.13 1 2678.5 -130.26 
∆UA,2S – GlcN 610.3 8.0 0.15 0.31 0.9747 1031.3 386.21 
∆UA,2S – GlcN, 6S 344.6 5.8 0.15 0.31 0.9785 686.75 262.55 
∆UA – GlcN, 6S 610.2 7.2 0.15 0.31 0.9876 1435.3 303.37 
∆UA – GlcN 530.2 9.4 0.15 0.31 0.9843 1381.2 341.58 
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Table 4: Recovery of Hep/HS DS following digestion, derivatization, and separation using 
the final protocol described above.  
Recovery (%) 
HS standard 
(µg) 
∆UA,2S – 
GlcNS,6S 
∆UA2S – 
GlcNS 
∆UA – 
GlcNS,6S 
∆UA – 
GlcNS 
∆UA – 
GlcNAc 
∆UA – 
GlcNAc,6S 
5 26.32 33.33 18.18 27.78 42.86 24.14 
10 26.67 35.71 30.77 39.02 43.02 33.33 
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Table 5. Composition of discaccahride subunits present in the cell lines tested. Top panel 
indicates concentrations (ng/mg dry weight). Bottom panel represents the relative 
abundance expressed as a percentage of total for each cell line.  
 
ng/mg dry weight  
DS subunit OVCAR MOLM-13 MDA-468 HCT-116 BeWo  
ΔUA,2S–GlcNS,6S 241.2 (3.11) 1197.5 (5.19) 110.2 (5.22) 256.0 (3.49) 203.9 (0.27)  
ΔUA,2S–GlcNS 97.0 (5.76) 235.6 (6.32) ND 78.2 (1.69) ND  
ΔUA–GlcNS,6S 74.9 (1.42) 84.0 (14.48) 61.7 (1.46) 98.4 (2.67) 65.2 (2.24)  
∆UA–GlcNS 210.8 (8.86) 252.6 (14.11 109.9 (2.08) 153.3 (1.56) 197.9 (2.66)  
ΔUA–GlcNAc 309.0 (3.95) 1095.1 (99.68) 121.3 (0.47) 259.8 (2.63) 326.9 (3.39)  
ΔUA,2S–GlcNAc  11.6 (0.63) 14.1 (0.40) ND ND 4.2 (0.94)  
∆UA–GlcNAc,6S 113.2 (1.31) 177.0 (0.67) 150.9 (7.04) 180.8 (4.80) 90.6 (0.95)  
Total 1058 (3.58) 3056 (7.26) 554 (3.25) 1027 (2.81) 889 (1.74)  
 
 
% total for cell line  
DS subunit OVCAR MOLM-13 MDA-468 HCT-116 BeWo HS 
ΔUA,2S–GlcNS,6S 22.8 (0.29) 39.2 (0.17) 19.9 (0.94) 24.9 (0.34) 22.9 (0.03) 8.2 (0.10) 
ΔUA,2S–GlcNS 9.2 (0.55) 7.7 (0.21) ND 7.6 (0.16) ND 0.5 (0.01) 
ΔUA–GlcNS,6S 7.1 (0.13) 2.7 (0.47) 11.1 (0.26) 9.6 (0.26) 7.3 (0.25) 8.7 (0.23) 
∆UA–GlcNS 19.9 (0.84) 8.3 (0.46) 19.8 (0.37) 14.9 (0.15) 22.3 (0.30) 12.6 (0.38) 
ΔUA–GlcNAc 29.2 (0.37) 35.8 (0.32) 21.9 (0.08) 25.3 (0.26) 36.8 (0.38) 48.0 (0.44) 
ΔUA,2S–GlcNAc  1.1 (0.06) 0.5 (0.01) ND ND 0.5 (0.11) 0.7 (0.01) 
∆UA–GlcNAc,6S 10.7 (0.12) 5.8 (0.02) 27.2 (1.27) 17.6 (0.47) 10.2 (0.11) 21.3 (0.19) 
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Figure 1a: LC-peak area as a function of the concentration of AMAC used for derivatization. 
Heparin/HS DS concentration: 2.5 µg/mL.  
 
 
 
 
 
 
 
 
 
 
Figure 1b: LC-peak area as a function of derivatization temperature of AMAC-derivatized 
heparin/HS DS standard. Heparin/HS DS concentration: 2.5 µg/mL. 
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Figure 1c: Selected ion recording (SIR) chromatogram of AMAC-derivatized ∆UA,2S – 
GlcNS,6S derivatized at 45 0C (top box) and 65 0C (bottom box) for 4 h showing loss of SO3- 
groups resulting in the formation of other DS during derivatization. Injection vol. 3 µL 
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Figure 1d: SIR chromatogram of ∆UA – GlcNS when derivatized at different temperatures. 
Top: 37 oC, middle: 45 oC, and bottom: 65 oC.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1e: LC-peak area against derivatization incubation time of AMAC-derivatized 
heparin/HS DS standard. Heparin/HS DS concentration: 2.5 µg/mL. 
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Figure 2a: LC-peak area of AMAC derivatized heparin/HS DS standard (1 µg/mL) as a 
function of cone voltage.  
 
Figure 2b: Mass spectrum of 100 µg/mL  AMAC-derivatized ∆UA,2S – GlcNS,6S (Top) 
obtained at a cone voltage of -20 and -60 V and ∆UA,2S – GlcNAc,6S (bottom) obtained at -
25 and -60 V  
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Figure 2c: LC-peak area against MS extractor voltage of AMAC-derivatized heparin/HS DS. 
Concentration: 1 µg/mL. 
 
 
Figure 2d: LC-peak area as a function of desolvation temperature of AMAC-derivatized 
heparin/HS DS. Concentration: 1 µg/mL. 
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Figure 2e: Mass spectrum of AMAC-derivatized ∆UA,2S – GlcNS,6S obtained at a cone 
voltage of -60 V and desolvation temperature of 350 0C (top) and 400 0C (bottom). Top 
number: m/z, bottom number: intensity 
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Figure 3: The SIR chromatograms of AMAC-derivatized heparin/HS DS using optimal 
derivatization and MS conditions. 10 µg/mL, injection volume: 5 µL 
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Figure 4: Bar chart and table showing the concentrations of recovered heparin/HS DS 
composition of heparan sulphate standard (µg/ml) and different cell lines (ng/mg dry 
weight). 
